- Cardiff Oncology press release ( NASDAQ: CRDF ): Q2 GAAP EPS of -$0.24 beats by $0.01 .
- Revenue of $0.09M (+28.6% Y/Y) beats by $0.02M .
-
As of June 30, 2022, Cardiff Oncology had approximately $122 million in cash, cash equivalents, and short-term investments.
-
Net cash used in operating activities for the second quarter of 2022 was approximately $6.7 million, an increase of approximately $2.4 million from $4.3 million for the same period in 2021.
For further details see:
Cardiff Oncology GAAP EPS of -$0.24 beats by $0.01, revenue of $0.09M beats by $0.02M